[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Schirmer et al., 2016 - Google Patents

Transgenic antigen-specific, HLA-A* 02: 01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity

Schirmer et al., 2016

View HTML @Full View
Document ID
14337042522342785100
Author
Schirmer D
Grünewald T
Klar R
Schmidt O
Wohlleber D
Rubío R
Uckert W
Thiel U
Bohne F
Busch D
Krackhardt A
Burdach S
Richter G
Publication year
Publication venue
Oncoimmunology

External Links

Snippet

Pediatric cancers, including Ewing sarcoma (ES), are only weakly immunogenic and the tumor-patients' immune system often is devoid of effector T cells for tumor elimination. Based on expression profiling technology, targetable tumor-associated antigens (TAA) are …
Continue reading at www.tandfonline.com (HTML) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes

Similar Documents

Publication Publication Date Title
Shafer et al. Cancer therapy with TCR-engineered T cells: current strategies, challenges, and prospects
JP7562623B2 (en) Claudin-18.2-specific immune receptors and T cell epitopes
US20220306711A1 (en) Claudin-6-specific immunoreceptors and t cell epitopes
Schirmer et al. Transgenic antigen-specific, HLA-A* 02: 01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity
Berger et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates
Kim et al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T-and B-cell responses
Deniger et al. Stable, nonviral expression of mutated tumor neoantigen-specific T-cell receptors using the sleeping beauty transposon/transposase system
Murad et al. Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy
Riet et al. Nonviral RNA transfection to transiently modify T cells with chimeric antigen receptors for adoptive therapy
Foltz et al. NCR1 expression identifies canine natural killer cell subsets with phenotypic similarity to human natural killer cells
WO2019118508A1 (en) Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
JP2020517308A (en) TCR and peptides
Blaeschke et al. Human HLA-A* 02: 01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo
Steger et al. CD4+ and CD8+ T-cell reactions against leukemia-associated-or minor-histocompatibility-antigens in AML-patients after allogeneic SCT
Rossi et al. Next generation natural killer cells for cancer immunotherapy
Kayser et al. Rapid generation of NY-ESO-1-specific CD4+ THELPER1 cells for adoptive T-cell therapy
van Leeuwen-Kerkhoff et al. Human bone marrow-derived myeloid dendritic cells show an immature transcriptional and functional profile compared to their peripheral blood counterparts and separate from slan+ non-classical monocytes
Donini et al. Cellular immunotherapy targeting cancer stem cells: preclinical evidence and clinical perspective
Dubreuil et al. Relevance of polymorphic KIR and HLA class I genes in NK-cell-based immunotherapies for adult leukemic patients
Davies et al. Robust production of merkel cell polyomavirus oncogene specific T cells from healthy donors for adoptive transfer
CN111212848A (en) BRAF-specific TCRs and uses thereof
Goff et al. Enhanced receptor expression and in vitro effector function of a murine-human hybrid MART-1-reactive T cell receptor following a rapid expansion
WO2020150832A1 (en) Cell-specific transcriptional regulatory sequences and uses thereof
KR20220031541A (en) Preparation of anti-BCMA CAR T cells
Boschert et al. H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient